BioStock: Aqilion takes aim at eosinophilic esophagitis with AQ280

Eosinophilic esophagitis is a challenging chronic inflammatory condition. Often leading to painful swallowing and food impaction, which can be fatal, EoE represents a significant area of unmet medical need where effective treatments are lacking. Enter Aqilion, who have just completed a phase I study with their candidate AQ280. BioStock spoke with CEO Sarah Fredriksson to learn more about the candidate and its potential in EoE management.

Read the interview with Aqilion's CEO Sarah Fredriksson at biostock.se:

https://www.biostock.se/en/2023/08/aqilion-tar-sikte-pa-eosinofil-esofagit-med-aq280/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/